VEGFR2

VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR or Kinase insert domain receptor, is a transmembrane receptor tyrosine kinase expressed predominantly on endothelial cells. It is the principal transducer of VEGF-A signaling and the dominant driver of new blood vessel formation in both physiological and pathological contexts.

Why it matters in peptide research

VEGFR2 activation initiates a cascade of intracellular events — including PI3K/Akt, MAPK/ERK, and eNOS pathways — that together promote endothelial cell proliferation, migration, and tube formation. Without adequate VEGFR2 signaling, tissues struggling to recover from injury cannot establish the vascular supply needed to deliver oxygen and nutrients to regenerating cells.

In the context of peptide research, VEGFR2 has attracted considerable attention because certain peptides appear capable of upregulating its expression or enhancing its downstream signaling without the systemic toxicity associated with small-molecule VEGFR agonists. This makes receptor modulation via peptides a potentially cleaner lever for promoting controlled angiogenesis in wound healing, muscle repair, and tendon remodeling.

BPC-157 is the most studied peptide in this regard. Preclinical data suggest BPC-157 upregulates VEGFR2 expression in vascular endothelium, which may explain its observed acceleration of wound closure and tendon-to-bone healing in animal models. The receptor upregulation appears to sensitize tissue to circulating VEGF, amplifying the angiogenic signal without requiring supraphysiological VEGF concentrations.

Peptides that act on this

• BPC-157 — preclinical evidence for VEGFR2 upregulation; associated with accelerated tissue repair and angiogenesis in tendon, gut, and muscle injury models.
• TB-500 (Thymosin Beta-4) — promotes VEGF expression upstream, indirectly increasing ligand availability for VEGFR2 signaling.

Common misconceptions

VEGFR2 activation is sometimes conflated with unrestricted tumor-promoting angiogenesis. In reality, physiological VEGFR2 signaling is tightly regulated by receptor internalization and negative feedback; the angiogenesis driven by peptide-mediated VEGFR2 upregulation in injury models is context-dependent and self-limiting once tissue repair is complete. Nonetheless, individuals with active malignancies should treat any angiogenic peptide with caution until human safety data mature.